When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Última revisão: 16 Mar 2025
Última atualização: 20 Nov 2024

Resumo

Definição

História e exame físico

Principais fatores diagnósticos

  • presença de fatores de risco
  • assintomático
  • polidipsia
  • poliúria

Outros fatores diagnósticos

  • infecções por cândida
  • infecções cutâneas
  • infecções do trato urinário
  • fadiga
  • visão turva
  • polifagia
  • perda de peso não intencional
  • parestesias
  • acantose nigricans

Fatores de risco

  • idade avançada
  • sobrepeso/obesidade
  • diabetes gestacional
  • hiperglicemia não diabética
  • história familiar de diabetes do tipo 2
  • ascendência não branca
  • síndrome do ovário policístico
  • hipertensão
  • dislipidemia
  • doença cardiovascular
  • estresse

Investigações diagnósticas

Primeiras investigações a serem solicitadas

  • glicemia de jejum
  • HbA1c
  • glicemia 2 horas após sobrecarga com ingesta de 75 g de glicose
  • glicemia plasmática aleatória

Investigações a serem consideradas

  • perfil lipídico em jejum
  • cetonúria
  • relação entre albumina e creatinina (RAC)
  • creatinina sérica e taxa de filtração glomerular (TFG) estimada
  • eletrocardiograma (ECG)
  • índice de pressão tornozelo-braquial (ITB)
  • peptídeo C aleatório
  • testagem de autoanticorpos
  • testes da função hepática

Algoritmo de tratamento

Colaboradores

Autores

Surya Rajeev, MBBS, MRCP, MD

Consultant Physician and Clinical Director

Department of Diabetes and Endocrinology

Liverpool University Hospital NHS Foundation Trust

UK

Declarações

SR has received reimbursement from Novo Nordisk for conferences, and has presented paid lectures.

Agradecimentos

Dr Surya Rajeev would like to gratefully acknowledge Dr Partha Kar, Dr Amar Puttanna, Dr Patrick J. O'Connor and Dr JoAnn M. Sperl-Hillen, the previous contributors to this topic.

Declarações

PK has sat on advisory boards and attended events reimbursed by Novo Nordisk, Eli Lilly, and Sanofi. AP has received honoraria from Napp, Novo Nordisk, Sanofi, Lilly-Boehringer Ingelheim, Daiichi-Sankyo, and AstraZeneca for presentation at meetings, conference registration, or participating in advisory boards. PJO receives research funding from the National Institutes of Health on multiple projects and is an author of a number of references cited in this topic. JMS-H is an author of a number of references cited in this topic and is an inventor on a US patent for Disease Treatment Simulation, a simulation-based technology developed without commercial support to educate health providers on chronic disease management in a virtual environment.

Revisores

Vinod Patel, MD, FRCP, FHEA, MRCGP, DRCOG, MBChB, BSc (Hons), RCPathME

Professor, Diabetes and Clinical Skills

Warwick Medical School

University of Warwick

Hon Consultant in Endocrinology and Diabetes, Acute Medicine, Medical Obstetrics

Diabetes and Endocrinology Centre

George Eliot Hospital NHS Trust

Nuneaton

Clinical Director for Diabetes West Midlands Clinical Networks & Clinical Senate

NHS England and NHS Improvement - Midlands

UK

Declarações

VP declares he has worked with most of the large pharmaceutical industry groups over the years with the majority of the work being in education of healthcare professionals in diabetes care. This includes Novo Nordisk, Eli Lily, MSD, BI, Sanofi, Napp, Internis, Takeda, and AZ. VP has been part of advisory board work on occasions. VP has received conference arrangements and lecture fees. VP is a trustee of the charity South Asian Health Foundation.

Gregory Lip, MD, FRCP, DFM, FACC, FESC, FEHRA

Price-Evans Professor of Cardiovascular Medicine

University of Liverpool

Senior Investigator

National Institute for Health Research

UK

Distinguished Professor

Faculty of Medicine

Aalborg University

Denmark

Adjunct Professor

Yonsei University

Seoul

South Korea

Declarações

GL has acted as a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, and Daiichi-Sankyo.

O uso deste conteúdo está sujeito ao nosso aviso legal